Skip to main content
. 2010 Mar 23;21(10):1999–2004. doi: 10.1093/annonc/mdq065

Figure 1.

Figure 1.

The Kaplan–Meier estimate of progression-free survival (PFS) in the 38 eligible patients with metastatic gastroesophageal junction cancer or gastric cancer who were treated with docetaxel, oxaliplatin, and bevacizumab. The dashed lines represent the 95% confidence interval (CI) about each successive estimate of the progression-free rate. The median PFS was 6.6 months (95% CI 4.4–10.5 months). The 6-month PFS rate was 55% (95% CI 35% to 74%).